

# CITATION REPORT

List of articles citing

**Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis**

**DOI: 10.1016/j.ahj.2010.06.004**

**American Heart Journal, 2010, 160, 543-51.**

**Source:** <https://exaly.com/paper-pdf/49577645/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
179	Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. <b>2010</b> , 4, 117-28		16
178	High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. <b>2011</b> , 58, 467-73		181
177	Speaker abstracts. <b>2011</b> , 12, 1-15		
176	Bibliography-Editors Selection of current word literature. <b>2011</b> , 22, 45-7		
175	Influence of platelet reactivity on outcome of patients with acute myocardial infarction undergoing primary angioplasty. <b>2011</b> , 75, 2050-1		2
174	Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. <b>2011</b> , 12, 1269-80		43
173	Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. <b>2011</b> , 5, 9-30		2
172	Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. <b>2011</b> , 27, 2117-22		4
171	Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. <b>2011</b> , 4, 505-13; discussion 513		14
170	Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. <b>2012</b> , 125, 1288-303; discussion 1303		45
169	Prevalence of poor biological response to clopidogrel: a systematic review. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 494-506	7	69
168	Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. <b>2012</b> , 10, 1999-2005		102
167	Antiplatelets in acute coronary syndrome: personal perspectives. <b>2012</b> , 10, 1487-96		8
166	Personalizing antiplatelet therapy with clopidogrel. <b>2012</b> , 92, 476-85		11
165	ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis. <i>Thrombosis Research</i> , <b>2012</b> , 129, 754-9	8.2	37
164	The concordance and correlation of measurements by multiple electrode and light transmittance aggregometries based on the pre-defined cutoffs of high and low on-treatment platelet reactivity. <i>Platelets</i> , <b>2012</b> , 23, 290-8	3.6	11
163	Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. <b>2012</b> , 17, 1447-85		54

162	Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. <b>2012</b> , 60, 369-77			37
161	Coagulation management in patients undergoing mechanical circulatory support. <b>2012</b> , 26, 179-98			65
160	Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. <b>2012</b> , 172, 1537-45			52
159	Personalized cardiovascular medicine: status in 2012. <i>Canadian Journal of Cardiology</i> , <b>2012</b> , 28, 693-9	3.8		8
158	Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?. <i>Platelets</i> , <b>2012</b> , 23, 167-76	3.6		3
157	InforMatrix: ADP antagonists in acute coronary syndromes. <b>2012</b> , 13, 357-85			
156	Impact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: platelet responsiveness and clinical outcome. <b>2012</b> , 42, 382-9			9
155	Personalised medicine: not just in our genes. <b>2012</b> , 344, e2161			33
154	Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 101-6	7		22
153	Resistance to clopidogrel: prevalence and associate variables. <b>2012</b> , 99, 1135-41			7
152	Platelet function testing in patients with coronary artery disease: is the Who and the When any clearer than the What and the What then?. <b>2012</b> , 125, 3073-5			8
151	Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 318-27	7		31
150	Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2012</b> , 34, 85-90	5.1		50
149	High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low?. <b>2012</b> , 10, 487-9			26
148	Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. <b>2012</b> , 42, 384-92			33
147	Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. <i>American Heart Journal</i> , <b>2013</b> , 166, 95-103	4.9		13
146	ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly. <b>2013</b> , 27, 779-95			12
145	Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , <b>2013</b> , 132, e15-8	8.2		23

144	Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease. <b>2013</b> , 6, 346-54		2
143	Clinical impact of genetically determined platelet reactivity. <b>2013</b> , 6, 398-403		5
142	Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 36, 1-6	5.1	4
141	Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know. <b>2013</b> , 11, 975-84		4
140	The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. <b>2013</b> , 2, 607-614		1
139	Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. <b>2013</b> , 167, 2018-23		94
138	A critical overview on ticagrelor in acute coronary syndromes. <b>2013</b> , 106, 105-15		15
137	Current evidence for monitoring platelet reactivity in acute coronary syndrome: a plea for individualized antiplatelet treatment. <b>2013</b> , 167, 1794-7		9
136	Avoiding stent thrombosis: advances in technique, antiplatelet pharmacotherapy and stent design. <b>2013</b> , 5, 179-201		
135	Preserved thrombin-inducible platelet activation in thienopyridine-treated patients. <b>2013</b> , 43, 689-97		15
134	Clopidogrel hyper-response and bleeding risk in neurointerventional procedures. <b>2013</b> , 34, 721-6		68
133	Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes. <b>2013</b> , 167, 995-9		11
132	Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. <b>2013</b> , 168, 403-6		25
131	A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. <b>2013</b> , 168, 4244-8		12
130	Switching acute coronary syndrome patients from prasugrel to clopidogrel. <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 158-65	5	53
129	Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity. <i>Thrombosis Research</i> , <b>2013</b> , 131, 508-13	8.2	76
128	Monitoring aspirin and clopidogrel response: testing controversies and recommendations. <b>2013</b> , 17, 123-37		5
127	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. <b>2013</b> , 167, 2140-8		102

126	Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate <sup>®</sup> analyser. <i>Platelets</i> , <b>2013</b> , 24, 303-7	3.6	32
125	Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis. <i>Platelets</i> , <b>2013</b> , 24, 352-61	3.6	31
124	Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel?. <b>2013</b> , 126, 233-43		7
123	Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?. <b>2013</b> , 8, 665-74		22
122	Tailoring antiplatelet therapy--insanity or good sense?. <b>2013</b> , 77, 1150-1		
121	Clinical importance of antiplatelet drugs in cardiovascular diseases. <b>2013</b> , 53, 81-96		18
120	High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 834-45	7	24
119	Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 808-16		32
118	Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction. <b>2013</b> , 2013, 313492		3
117	Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 517-24	7	12
116	ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS?. <i>Rational Pharmacotherapy in Cardiology</i> , <b>2013</b> , 9, 682-689	0.5	2
115	A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel. <i>Platelets</i> , <b>2014</b> , 25, 612-8	3.6	23
114	Pharmacogenomics of Clopidogrel. <b>2014</b> , 509-541		1
113	Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes. <b>2014</b> , 12, 1289-303		3
112	The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A2-dependent platelet reactivity. <i>Platelets</i> , <b>2014</b> , 25, 268-73	3.6	5
111	The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis. <b>2014</b> , 2014, 610296		12
110	Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , <b>2014</b> , 35, 209-15	9.5	190
109	The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. <b>2014</b> , 100, 192-9		17

108	Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. <b>2014</b> , 12, 736-47		65
107	Glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or TIA. <i>Platelets</i> , <b>2014</b> , 25, 102-10	3.6	19
106	The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome. <b>2014</b> , 30, 2151-67		1
105	Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. <b>2014</b> , 1, e000068		31
104	Risk of stroke in patients with high on-clopidogrel platelet reactivity to adenosine diphosphate after percutaneous coronary intervention. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1807-14	3	5
103	Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass. <i>American Heart Journal</i> , <b>2014</b> , 167, 818-25	4.9	6
102	Relationship between changes in platelet reactivity and ischemic events following percutaneous coronary intervention: a meta-regression analysis of 30 randomized trials. <i>Atherosclerosis</i> , <b>2014</b> , 234, 176-84	3.1	15
101	First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor. <i>Platelets</i> , <b>2014</b> , 25, 636-8	3.6	9
100	Role of phenotypic and genetic testing in managing clopidogrel therapy. <b>2014</b> , 124, 689-99		26
99	Vasodilator-Stimulated Phosphoprotein (VASP) Assay. <b>2014</b> , 58-64		
98	The Path to Personalized Cardiovascular Medicine. <b>2014</b> , 837-871		
97	Clopidogrel Resistance. <b>2014</b> , 285-292		1
96	Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry. <b>2014</b> , 4, 188-192		3
95	Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy. <i>Thrombosis Research</i> , <b>2014</b> , 134, 96-104	8.2	5
94	Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 311-22	7	7
93	Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 273-8	7	53
92	Cardiovascular drugs and the genetic response. <b>2014</b> , 10, 13-7		7
91	Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding?. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 221-30	7	28

90	High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention: a meta-analysis. <b>2015</b> , 26, 386-95		4
89	Assessment of steady-state clopidogrel reactivity by using platelet reactivity units. <b>2015</b> , 22, 182-5		1
88	ATLANTIC: another reason to investigate the disconnect between stent thrombosis and mortality?. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 9-10	7	
87	P2Y12 inhibitors for acute coronary syndromes: current perspectives. <b>2015</b> , 123		
86	INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. <i>Rational Pharmacotherapy in Cardiology</i> , <b>2015</b> , 11, 344-354	0.5	
85	EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME. <i>Rational Pharmacotherapy in Cardiology</i> , <b>2015</b> , 11, 359-364	0.5	
84	The effect of acenocoumarol on the antiplatelet effect of clopidogrel. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 708-16	7	3
83	The Emerging Role of miR-223 in Platelet Reactivity: Implications in Antiplatelet Therapy. <b>2015</b> , 2015, 981841		35
82	The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients. <b>2015</b> , 75, 223-9		7
81	Meta-analysis appraising high maintenance dose clopidogrel in patients who underwent percutaneous coronary intervention with and without high on-clopidogrel platelet reactivity. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 592-601	3	5
80	The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study. <b>2015</b> , 14, 15		29
79	Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy. <i>Current Atherosclerosis Reports</i> , <b>2015</b> , 17, 501	6	2
78	Clinical efficacy and safety of cilostazol: a critical review of the literature. <i>Drugs</i> , <b>2015</b> , 75, 377-95	12.1	37
77	Antiplatelet Therapy and Anticoagulation. <b>2015</b> , 109-130		
76	Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel: results from Assessing Platelet Activity in Coronary Heart Disease (APACHE). <i>Thrombosis Research</i> , <b>2015</b> , 136, 335-40	8.2	4
75	Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2015</b> , 40, 70-5	5.1	19
74	Antiplatelet treatment in essential hypertension: where do we stand?. <i>Current Hypertension Reports</i> , <b>2015</b> , 17, 536	4.7	2
73	Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2015</b> , 24, 2348-57	2.8	10



72	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , <b>2015</b> , 170, 683-694.e3	4.9	22
71	Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome. <i>Platelets</i> , <b>2015</b> , 26, 467-73	3.6	23
70	Perioperative Hemostasis. <b>2015</b> ,		2
69	CLINICAL AND LABORATORY CHARACTERISTICS OF PATIENTS WITH ISCHEMIC HEART DISEASE RESISTANT TO ACETYLSALICYLIC ACID IN PERIOPERATIVE PERIOD OF CORONARY ARTERY BYPASS GRAFT: RESULTS OF AN OPEN PROSPECTIVE STUDY. <i>Rational Pharmacotherapy in Cardiology</i> , <b>2016</b> , 12, 265-271	0.5	3
68	Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials. <i>Chinese Medical Journal</i> , <b>2016</b> , 129, 984-91	2.9	5
67	Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention. <i>Rational Pharmacotherapy in Cardiology</i> , <b>2016</b> , 12, 528-535	0.5	4
66	Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 844-55	7	26
65	Peri-procedural Platelet Function Testing in Risk Stratification and Clinical Decision Making. <b>2016</b> , 453-458		
64	Assessment of platelet function in patients receiving tirofiban early after primary coronary intervention. <i>Interventional Medicine &amp; Applied Science</i> , <b>2016</b> , 8, 135-140	0.7	1
63	Immediate response to prasugrel loading in patients with ST-elevation myocardial infarction: Predictors and outcome. <i>Thrombosis Research</i> , <b>2016</b> , 144, 176-81	8.2	1
62	Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting. <i>Atherosclerosis</i> , <b>2016</b> , 251, 305-310	3.1	7
61	Anti-platelet Therapy Resistance - Concept, Mechanisms and Platelet Function Tests in Intensive Care Facilities. <i>The Journal of Critical Care Medicine</i> , <b>2016</b> , 2, 6-15	1.2	9
60	Toll-like receptor 9 expression and activation in acute coronary syndrome patients on dual anti-platelet therapy. <i>Thrombosis Research</i> , <b>2016</b> , 148, 89-95	8.2	15
59	Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study. <i>Platelets</i> , <b>2016</b> , 27, 791-795	3.6	1
58	Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 42, 186-96	5.1	2
57	Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity. <i>Journal of Breath Research</i> , <b>2016</b> , 10, 017104	3.1	13
56	Platelet Function Testing in Patients on Antiplatelet Medications. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2016</b> , 42, 306-20	5.3	28
55	Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , <b>2016</b> , 139, 114-20	8.2	11



54	Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 656-663	3	11
53	Personalized Antiplatelet Therapy: The Odyssey Continues. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 105-106	5	1
52	Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome. <i>Platelets</i> , <b>2016</b> , 27, 159-67	3.6	7
51	On-treatment platelet reactivity: State of the art and perspectives. <i>Vascular Pharmacology</i> , <b>2016</b> , 77, 8-18	5.9	12
50	Diabetes mellitus and carotid artery plaques exhibiting high-intensity signals on MR angiography are related to increased platelet reactivity after carotid artery stenting. <i>Journal of NeuroInterventional Surgery</i> , <b>2017</b> , 9, 106-110	7.8	5
49	Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2017</b> , 26, 1864-1873	2.8	11
48	Optimal pediatric dosing of anti-platelet agents for pipeline stent embolization -a case report and review of the literature. <i>Child's Nervous System</i> , <b>2017</b> , 33, 685-690	1.7	13
47	Antiplatelet Effect of Different Loading Doses of Ticagrelor in Patients With Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The APELOT Trial. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 1675-1682	3.8	4
46	High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2017</b> , 26, 2074-2081	2.8	14
45	Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. <i>Journal of Interventional Cardiology</i> , <b>2017</b> , 30, 457-464	1.8	6
44	Clinical outcomes in patients treated for coronary in-stent restenosis with drug-eluting balloons: Impact of high platelet reactivity. <i>PLoS ONE</i> , <b>2017</b> , 12, e0188493	3.7	2
43	Comparison of Platelet Function Guided Versus Unguided Treatment With P2Y12 Inhibitors in Patients With Acute Myocardial Infarction (from the Hungarian Myocardial Infarction Registry). <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 1129-1137	3	9
42	Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy. <i>European Heart Journal</i> , <b>2018</b> , 39, 193-200	9.5	3
41	Impact of Test Conditions on ADP-Induced Platelet Function Results With the Multiplate Assay: Is Further Standardization Required?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2018</b> , 23, 149-154	2.6	4
40	A Remote Assay for Measuring Canine Platelet Activation and the Inhibitory Effects of Antiplatelet Agents. <i>Journal of Veterinary Internal Medicine</i> , <b>2018</b> , 32, 119-127	3.1	3
39	Monitoring platelet function: what have we learned from randomized clinical trials?. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2018</b> , 8, 621-629	2.6	5
38	Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial. <i>BMC Cardiovascular Disorders</i> , <b>2018</b> , 18, 201	2.3	1
37	Diabetes and Cardiovascular Disease. <b>2018</b> , 823-838		

36	Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1606-1616	7	5
35	Relationship of Platelet Reactivity and Inflammatory Markers to Recurrent Adverse Events in Patients with ST-Elevation Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1785-1794	7	6
34	Emerging Factors Implicated in Fibrotic Organ-Associated Thrombosis: The Case of Two Organs. <i>TH Open</i> , <b>2019</b> , 3, e165-e170	2.7	2
33	Platelet Function Testing in Neurovascular Procedures: Tool or Gimmick?. <i>Interventional Neurology</i> , <b>2020</b> , 8, 123-134	3	6
32	Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner?. <i>Thrombosis Research</i> , <b>2019</b> , 176, 133-139	8.2	3
31	Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. <i>Frontiers in Cardiovascular Medicine</i> , <b>2019</b> , 6, 176	5.4	12
30	High plateletcrit is associated with early loss of patency after open and endovascular interventions for chronic limb ischemia. <i>Journal of Vascular Surgery</i> , <b>2020</b> , 71, 2089-2097	3.5	0
29	Ticagrelor in the management of coronary artery disease. <i>Future Cardiology</i> , <b>2021</b> , 17, 561-571	1.3	0
28	Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis. <i>Journal of Neurology</i> , <b>2020</b> , 267, 3021-3037	5.5	10
27	Screening on platelet LncRNA expression profile discloses novel residual platelet reactivity biomarker. <i>International Journal of Laboratory Hematology</i> , <b>2020</b> , 42, 661-668	2.5	3
26	Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	8
25	Genetic polymorphisms of high platelet reactivity in Chinese patients with coronary heart disease under clopidogrel therapy. <i>International Journal of Clinical Pharmacy</i> , <b>2020</b> , 42, 158-166	2.3	2
24	Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 468-472	5.1	13
23	Impact of high on-treatment platelet reactivity after angioplasty in patients with peripheral arterial disease. <i>Platelets</i> , <b>2021</b> , 32, 391-397	3.6	4
22	MiR-223-3p in Cardiovascular Diseases: A Biomarker and Potential Therapeutic Target. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 610561	5.4	12
21	Clinical significance of high on-treatment platelet reactivity in patients with prolonged clopidogrel therapy. <i>Korean Journal of Internal Medicine</i> , <b>2021</b> , 36, S80-S89	2.5	
20	Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	0
19	MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 652579	4.6	6

18	Discordance Between VASP Phosphorylation and Platelet Aggregation in Defining High On-Clopidogrel Platelet Reactivity After ST-Segment Elevation Myocardial Infarction. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 47-54	3.3	1
17	Current Concepts in the Clinical Utility of Platelet Reactivity Testing. <i>Interventional Cardiology Review</i> , <b>2013</b> , 8, 100-106	4.2	2
16	Platelet function monitoring in patients on clopidogrel. <i>Interventional Medicine &amp; Applied Science</i> , <b>2011</b> , 3, 32-38	0.7	1
15	The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. <i>EuroIntervention</i> , <b>2013</b> , 9, 316-27	3.1	27
14	Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications. <i>World Journal of Cardiology</i> , <b>2015</b> , 7, 912-21	2.1	20
13	Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on-treatment platelet reactivity: the OPTimal Management of Antithrombotic Agents (OPTIMA)-2 Trial. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	1
12	Clinical assessment, platelet reactivity measurement or genetic testing after acute coronary syndrome? What benefits the patient?. <i>EuroIntervention</i> , <b>2013</b> , 9, 299-301	3.1	3
11	Impact of Antiplatelet Therapy and Platelet Reactivity Testing on Cardiovascular Outcomes in Patients with Chronic Kidney Disease. <b>2017</b> , 301-313		
10	Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor. <i>European Cardiology Review</i> , <b>2019</b> , 14, 175-178	3.9	2
9	The role of miRNAs in regulation of platelet activity and related diseases - a bioinformatic analysis.. <i>Platelets</i> , <b>2022</b> , 1-13	3.6	1
8	Platelet transmission electron microscopy for the assessment of poor biological response to antiplatelet agent: pilot descriptive and prospective study - ELECTROSTROKE.. <i>BMJ Open</i> , <b>2022</b> , 12, e050060		
7	genetic polymorphism and incidence of in-stent restenosis in patients on clopidogrel: a matched case-control study. <i>Drug Metabolism and Personalized Therapy</i> , <b>2021</b> ,	2	1
6	Prediction of residual ischemic risk in ticagrelor-treated patients with acute coronary syndrome.. <i>Thrombosis Journal</i> , <b>2022</b> , 20, 21	5.6	0
5	Peri-procedural Platelet Function Testing in Risk Stratification and Clinical Decision Making. <b>2022</b> , 483-490		
4	Clinical Impact of Platelet Reactivity and Gene Polymorphisms in Patients With Ischemic Heart Disease After Percutaneous Coronary Intervention. <b>2022</b> , 1, 168		0
3	Abatement of potent P2Y12 antagonist-based dual antiplatelet therapy after coronary intervention: A network meta-analysis of randomized controlled trials. 9,		0
2	Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy.		0
1	Monitoring antiplatelet therapy: where are we now?. <b>2023</b> , 24, e24-e35		0

